Hauser Announces Licensing of Paclitaxel Technology

LONG BEACH, Calif. and LONGMONT, Colo., March 14, 2002 (PRIMEZONE) -- Hauser, Inc. (OTCBB:HAUS) today announced an agreement to license certain intellectual property and provide consulting services to Tisorex, a company headquartered in Fort Lee, New Jersey, which has been formed to produce bulk paclitaxel using raw material harvested from Taxus Bacata trees in the Republic of Georgia. As part of the transaction Hauser sold certain manufacturing assets to Tisorex and will receive royalties from Tisorex paclitaxel sales as well as payment for technical services.

Hauser, headquartered in Long Beach, California and Longmont, Colorado, is a leading supplier of herbal extracts and nutritional supplements. The company also provides interdisciplinary laboratory testing services, chemical engineering services, and contract research and development. The company's products and services are principally marketed to the pharmaceutical, dietary supplement and food ingredient businesses. Hauser's business units include: Botanicals International Extracts, Shuster Laboratories, ZetaPharm and Hauser Contract Research Organization.

Certain oral and written statements of management of the Company included in this Press Release and elsewhere may contain forward-looking statements within the meaning of Section 27A of the Securities Exchange Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are intended to be covered by the safe harbors created thereby. These statements include the realization of possible future revenue from sales of paclitaxel, the reduction of overhead and/or operating expenses and the plans and objectives of management for future operations. The forward-looking statements included herein and elsewhere are based on current expectations that involve judgments which are difficult or impossible to predict accurately and many of which are beyond the control of the Company. Although the Company believes that the assumptions underlying the forward-looking statements are reasonable, any of the assumptions could be inaccurate and, therefore, there can be no assurance that the forward-looking statements will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements, the inclusion of such information should not be regarded as a representation by the Company or any other person that the objectives and plans of the Company will be achieved.



Contact Data